{"groups":[{"description":"Ibrutinib PO 560mg + Carfilzomib IV 20/27 mg/m2\n\nIbrutinib\n\nCarfilzomib","id":"FG000","title":"Cohort 1 (560 mg)"},{"description":"Ibrutinib PO 560 mg + Carfilzomib IV 20/36 mg/m2\n\nIbrutinib\n\nCarfilzomib","id":"FG001","title":"Cohort 2a (560 mg)"},{"description":"Ibrutinib PO 560 mg+ Carfilzomib IV 20/36 mg/m2 Dexamethasone PO 20 mg\n\nIbrutinib\n\nCarfilzomib\n\nDexamethasone","id":"FG002","title":"Cohort 2b (560 mg)"},{"description":"Ibrutinib PO 840 mg + Carfilzomib IV 20/36 mg/m2 + Dexamethasone PO 20 mg\n\nIbrutinib\n\nCarfilzomib\n\nDexamethasone","id":"FG003","title":"All RP2D (840 mg)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"17"},{"groupId":"FG003","numSubjects":"59"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"17"},{"groupId":"FG003","numSubjects":"59"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"A total of 84 participants were enrolled and received at least 1 dose of study treatment (All-treated population); of these participants, a total of 59 received treatment at the recommended Phase 2 dose of study drug (All RP2D population)."}